Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 50%Low 0 · 0%Moderate 1 · 50%High 0 · 0%

Adverse events ( · people with mild/moderate/severe/critical COVID‐19

Tociliuzumab showed no clear difference in adverse events ( compared with standard care/placebo (moderate certainty).

1 finding from 1 review

Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes only
RR 1.03 [0.95, 1.12]
9 studies · 1811 participants
Moderate

Serious adverse events ( · people with mild/moderate/severe/critical COVID‐19

It is very uncertain whether tociliuzumab changes serious adverse events ( compared with standard care/placebo (very low certainty).

1 finding from 1 review

Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes only
RR 0.93 [0.81, 1.07]
16 studies · 2974 participants
Very low